Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Community Clinical Oncology Program (CCOP), Minority-Based CCOP (MBCCOP), and Research Base Principal Investigator and Administrator Meeting

September 24, 2012 Breakout Sessions – run concurrently from 2:45 pm – 4:15 pm

I. Measuring Clinical Trial Workload in a Community-Based Setting

Presenter: Marge Good, RN, MPH, OCN
Panel: Terri Stewart, MHA and Connie Szczepanek, RN, BSN

There are many challenges associated with the management of today's cancer clinical trials. One challenge that remains unanswered is determining what a manageable workload is for research staff. This session will describe workload measurement tools currently being utilized as well as the results of one community-based site's efforts to measure workload. The goal of the session will be to discuss a potential tool to be utilized within the CCOP/MBCCOP network.

II. NCCCP Exemplary Community Research Site Practices

Presenters: Stephen Grubbs, MD and Kandie Dempsey, MS, RN

The data analysis evaluating the NCI's Community Cancer Centers Program (NCCCP) Clinical Trial Matrix (CT Matrix) measurement tool will be presented in this session. The tool development is based on the Journal of Clinical Oncology (JCO) publication entitled, "American Society of Clinical Oncology Statement on Minimum Standards and Exemplary Attributes of Clinical Trial Sites," (Zon, R., et al, JCO, May 2008).  The analysis centers on two years of data evaluating the 9 CT Matrix "best practice indicators" from 28 participating NCCCP sites.  The overall goal of this session is to familiarize CCOP/MBCCOP Programs with the tool and gather feedback on the tool's potential utility in community research infrastructure development.

III. Clinical Research Billing Compliance

Presenters: Kelly Willenberg, MBA, BSN, CHC, CHRC and Lora Black, BA, RN, OCN, CCRP

The importance of research billing compliance and how it may impact the hospital and oncology practice will be discussed. Possible designs and implementation processes that may assist in the identification and tracking of all research subjects receiving services within the health system as a means to ensure proper billing will also be presented.

IV. Late Toxicities and Research Issues in Cancer Survivors

Presenters: Joanna Brell, MD (moderator) Craig Nichols, MD, Lynn Wagner, PhD, Julia Rowland, PhD, and Karen Mustian, PhD

This session is geared toward medical oncologists and survivorship researchers. After a brief introduction, it will feature 4 experts who will speak on the following topics:

  • Chronic toxicity in testicular cancer survivors
  • Psychosocial issues in cancer survivors;
  • National research agenda on survivorship; and
  • Important aspects of conducting survivorship research

There will be a panel after the presentations to answers questions and discuss pertinent issues from the session participants.

The objectives of the session are to

  • Improve recognition of post-therapy toxicities that are important to patients
  • Enumerate compelling research questions in survivorship research
  • Understand issues in conducting survivorship research